Ustekinumab Safe, effectual in Long-Term Psoriasis attention Medscape February 29, 2012 — Researchers have recovered that ustekinumab (Stelara, Janssen Biotech, Inc.), a new interleukin 12 (IL-12) and IL-23 antagonist, has type A favorable benefit–risk profile for up to 3 age of treatment for average to severe psoriasis . Link To Article
No comments:
Post a Comment